{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG000","lowerLimit":"2.07","upperLimit":"NA","value":"5.72"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG001","lowerLimit":"1.35","upperLimit":"NA","value":"2.83"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG002","lowerLimit":"4.84","upperLimit":"NA","value":"6.10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"PFS is defined as the time from randomization to the first documented progressive disease or death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with select solid tumor types received epacadostat 100 mg BID in combination with nivolumab 360 mg, IV, Q2W, on Day 1 of each 21-day cycle along with 5-FU/Platinum chemotherapy regimen IV. Participants were de-escalated to epacadostat 50 mg BID if 100 mg was not tolerated.","id":"OG000","title":"Phase 1, Part 2: Epacadostat 100 mg + Nivolumab 360 mg + 5-FU/Platinum"},{"description":"Participants with select solid tumor types received epacadostat 100 mg BID in combination with nivolumab 360 mg, IV, Q2W, on Day 1 of each 21-day cycle along with Pemetrexed /Platinum chemotherapy regimen IV. Participants were de-escalated to epacadostat 50 mg BID if 100 mg was not tolerated.","id":"OG001","title":"Phase 1, Part 2: Epacadostat 100 mg + Nivolumab 360 mg + Pemetrexed/ Platinum"},{"description":"Participants with select solid tumor types received epacadostat 100 mg BID in combination with nivolumab 360 mg, IV, Q2W, on Day 1 of each 21-day cycle along with Paclitaxel/Platinum chemotherapy regimen IV. Participants were de-escalated to epacadostat 50 mg BID if 100 mg was not tolerated.","id":"OG002","title":"Phase 1, Part 2: Epacadostat 100 mg + Nivolumab 360 mg + Paclitaxel/ Platinum"}],"paramType":"MEDIAN","populationDescription":"The Phase 1, Part 2 Full Analysis Population includes all participants enrolled in the study who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From first dose up end of the study (up to approximately 6 years)","title":"Phase 1, Part 2: PFS for Participants With Advanced or Metastatic SCCHN and Advanced or Metastatic NSCLC","type":"SECONDARY","unitOfMeasure":"months"}